Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines

Abdelilah, Soussi Gounni; Wellemans, Vincent; Agouli, Mourad; Guenounou, Moncef; Hamid, Qutayba; Beck, Lisa A.; Lamkhioued, Bouchaïb

doi:10.1016/j.clim.2006.03.014

Cited by 72 publications

(58 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous reports suggested a contribution of Th2 to the pathogenesis of BP [12,14]. To confirm these previous findings, we employed immunohistochemical staining of IL-4, IL-13 as well as pSTAT1 and pSTAT6 for BP and PV.…”

Section: Resultsmentioning

confidence: 95%

Comparison of CD163+ CD206+ M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid

et al. 2014

View full text Add to dashboard Cite

Background: M2 macrophages play a critical role in the induction of T helper 2 (Th2) polarization. Methods: To investigate the contribution of M2 macrophages to the pathogenesis of bullous pemphigoid (BP) and pemphigus vulgaris (PV), we employed immunohistochemical staining for CD163 and CD206, as well as pSTAT1, pSTAT6, interleukin (IL)-4, IL-13, CCL17, CCL18 and Foxp3 in the lesional skin of 10 cases of BP and PV. Results: The numbers of CD163+ CD206+ M2 macrophages were higher in BP than in PV. Moreover, pSTAT6+ cells, CCL17+ cells, CCL18+ cells and Foxp3+ regulatory T cells were prominent only in the lesional skin of BP. To further investigate the function of M2 macrophages, we examined the mRNA expression and production of Th2-related chemokines from M2 macrophages in vitro, which showed a significant increase in the mRNA expression and production of CCL18 when stimulated by IL-4 or IL-13. Conclusion: Our study sheds light onto one of the possible immunological mechanisms of BP and PV.

show abstract

Section: Resultsmentioning

confidence: 95%

Comparison of CD163+ CD206+ M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Such a condition may trigger BP, as Gounni Abdelilah et al . reported the involvement of Th2‐associated chemokines (eotaxin and monocyte chemoattractant protein‐4) in the pathogenesis of BP . Conversely, it was reported that ustekinumab could improve clinical manifestation in psoriasis patients without affecting T‐cell immune response .…”

Section: Discussionmentioning

confidence: 99%

Development of bullous pemphigoid during treatment of psoriatic onycho‐pachydermo periostitis with ustekinumab

Nakayama

Fujita

Watanabe

et al. 2015

The Journal of Dermatology

View full text Add to dashboard Cite

Ustekinumab is a human monoclonal antibody that specifically binds to the p40 subunit of interleukin (IL)-12 and IL-23, inhibiting the activity of both cytokines, thereby blocking the T-helper (Th)1 and Th17 inflammatory pathways. While biologic agents have dramatically changed the strategies of psoriasis treatment, increasing cases of autoimmune diseases during the use of such agents have been reported. We experienced a case of bullous pemphigoid occurring during treatment of a rare variant of psoriatic arthritis, psoriatic onycho-pachydermo periostitis with ustekinumab. Only six cases of autoimmune blistering diseases during treatment with biologic agents have ever been reported including our case, and we herein review the published work of these cases. Dermatologists must be attentive to the possibility of autoimmune blistering diseases during ustekinumab treatment.

show abstract

“…The inhibitory properties of TNF-targeted therapies suggest that the immunological state of the treated patients shifts from Th1 to Th2 dominance, which is known to be involved in autoimmune bullous skin disease such as bullous pemphigoid [19,20] or pemphigus [21]. …”

Section: Discussionmentioning

confidence: 99%

Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

et al. 2010

View full text Add to dashboard Cite

Background: Anti-tumor necrosis factor (TNF) agents are increasingly being used for a rapidly expanding number of rheumatic and systemic diseases. As a result of this use, and of the longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. The use of anti-TNF agents has been associated with more and more cases of autoimmune diseases, principally cutaneous vasculitis, lupus-like syndrome, systemic lupus erythematosus and interstitial lung disease. Observations: We report 2 cases of autoimmune bullous skin disease occurring in patients undergoing TNF-targeted therapy: a bullous pemphigoid and a pemphigus foliaceus. Both patients were treated by anti-TNF agents for rheumatoid arthritis and showed improvement following interruption of that treatment. Here, we discuss the relationship between anti-TNF therapy and the occurrence of autoimmune bullous disease. Conclusion: Anti-TNF agents should be considered as a potential cause of drug-induced autoimmune bullous skin disease.

show abstract

Increased expression of Th2-associated chemokines in bullous pemphigoid disease. Role of eosinophils in the production and release of these chemokines

Cited by 72 publications

References 43 publications

Comparison of CD163+ CD206+ M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid

Comparison of CD163+ CD206+ M2 Macrophages in the Lesional Skin of Bullous Pemphigoid and Pemphigus Vulgaris: The Possible Pathogenesis of Bullous Pemphigoid

Development of bullous pemphigoid during treatment of psoriatic onycho‐pachydermo periostitis with ustekinumab

Autoimmune Bullous Skin Diseases Occurring under Anti-Tumor Necrosis Factor Therapy: Two Case Reports

Contact Info

Product

Resources

About